Tofacitinib citrate (CP-690,550-10) is currently being evaluated for the treatment of rheumatoid arthritis, psoriasis and other diseases. An NDA has recently been submitted to the FDA for the treatment of rheumatoid arthritis. The Pfizer Tofacitinib API Team has worked to improve the efficiency of the process and ensure that the quality of the drug substance will meet the standards of the regulatory agencies. Quality by Design is important not only from a regulatory perspective, but also from a process development perspective since it enforces a much more thorough degree of process understanding. DOE is often the focus of QbD but there are often other techniques (experimental and modeling) that can be used in the development of a process. This talk will provide examples of how we use these various techniques to ensure we have a robust process that can be run at a wide range of scales and consistently meet our quality standards.
Watch the following preview of this presentation.
Would you like to access this content?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
-
Log in
You must be logged in to view this content. Log in now.
-
Purchase Technical Presentation
You must purchase this technical presentation using one of the options below.
If you already purchased this content recently, please click here to refresh the system's record of ownerships.
Pricing
| Credits | 0.5 Use credits |
| List Price | $25.00 Buy now |
| AIChE Members | $15.00 Buy now |
| AIChE Undergraduate Student Members | Free Free access |
| AIChE Graduate Student Members | $15.00 Buy now |